financetom
Business
financetom
/
Business
/
Royal Caribbean Group Seen Offering Outlook on Earnings, Investments, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Royal Caribbean Group Seen Offering Outlook on Earnings, Investments, UBS Says
Feb 26, 2025 8:59 AM

11:32 AM EST, 02/26/2025 (MT Newswires) -- Royal Caribbean Group (RCL) is expected to provide three-year targets on earnings and returns on investments, UBS Securities said Wednesday in a report.

The 2027 earnings target announced at investor day may be $20 a share versus the consensus of $19.88, said UBS, which projects $20.33.

The company may a 30% return on investment after spending $700 million on Perfect Day Mexico, a private destination set to open in 2027, UBS said.

With a return to investment grade metrics," the company may unveil a plan for capital return to shareholders, UBS said.

UBS maintained its buy rating on Royal Caribbean stock with a price target at $301.

The company's shares rose 3.6% in recent Wednesday trading.

Price: 246.04, Change: +8.47, Percent Change: +3.57

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Symbotic Fiscal Q3 Loss Narrows, Revenue Rises; Q4 Revenue Outlook Set; Shares Fall After Hours
Symbotic Fiscal Q3 Loss Narrows, Revenue Rises; Q4 Revenue Outlook Set; Shares Fall After Hours
Jul 29, 2024
04:34 PM EDT, 07/29/2024 (MT Newswires) -- Symbotic ( SYM ) reported a fiscal Q3 loss Monday of $0.02 per diluted share, narrower than a loss of $0.07 a year earlier. Analysts polled by Capital IQ expected breakeven. Revenue in the quarter ended June 29 rose to $491.8 million from $311.8 million a year earlier. Analysts surveyed by Capital IQ...
Sanofi sues Sarepta over US patents for gene therapy treatments
Sanofi sues Sarepta over US patents for gene therapy treatments
Jul 29, 2024
July 29 (Reuters) - Sanofi-owned biotech company Genzyme has sued rival Sarepta Therapeutics ( SRPT ) in Delaware federal court for allegedly infringing two patents related to Sarepta's Duchenne muscular dystrophy (DMD) treatment Elevidys. Genzyme said in the lawsuit, made public on Monday, that Sarepta mimics Genzyme's technology for modifying viruses used to deliver genes into human cells in gene-therapy...
Renaissancere Holdings Insider Sold Shares Worth $561,400, According to a Recent SEC Filing
Renaissancere Holdings Insider Sold Shares Worth $561,400, According to a Recent SEC Filing
Jul 29, 2024
04:33 PM EDT, 07/29/2024 (MT Newswires) -- Robert Qutub, Executive Vice President, Chief Financial Officer, on July 26, 2024, sold 2,500 shares in Renaissancere Holdings ( RNR/PF ) for $561,400. Following the Form 4 filing with the SEC, Qutub has control over a total of 73,915 shares of the company, with 73,915 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/913144/000091314424000100/xslF345X03/wk-form4_1722284904.xml Price: 226.94,...
Element Solutions Q2 Adjusted Earnings, Net Sales Rise
Element Solutions Q2 Adjusted Earnings, Net Sales Rise
Jul 29, 2024
04:31 PM EDT, 07/29/2024 (MT Newswires) -- Element Solutions ( ESI ) reported Q2 adjusted earnings late Monday of $0.36 per share, up from $0.31 a year earlier. Analysts surveyed by Capital IQ expected $0.35. Net sales in the quarter ended June 30 rose to $612.7 million from $586.1 million a year earlier. Analysts surveyed by Capital IQ expected $608.3...
Copyright 2023-2026 - www.financetom.com All Rights Reserved